NL195004C
(nl)
*
|
1987-03-04 |
2003-11-04 |
Novartis Ag |
Fenylcarbamaat bevattend farmaceutisch preparaat.
|
JP3598116B2
(ja)
*
|
1994-04-15 |
2004-12-08 |
雅臣 伊豫 |
遅発性ジスキネジアの治療用医薬組成物とその利用
|
CA2275371C
(en)
*
|
1996-12-18 |
2008-07-29 |
Teva Pharmaceutical Industries, Ltd. |
Phenylethylamine derivatives
|
US6251938B1
(en)
|
1996-12-18 |
2001-06-26 |
Teva Pharmaceutical Industries, Ltd., |
Phenylethylamine derivatives
|
DE69738275T2
(de)
|
1996-12-18 |
2008-08-28 |
Teva Pharmaceutical Industries Ltd. |
Aminoindanderivate
|
US6316023B1
(en)
*
|
1998-01-12 |
2001-11-13 |
Novartis Ag |
TTS containing an antioxidant
|
GB9800526D0
(en)
*
|
1998-01-12 |
1998-03-11 |
Ciba Geigy Ag |
Organic compounds
|
US6218383B1
(en)
|
1998-08-07 |
2001-04-17 |
Targacept, Inc. |
Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
|
DE69923200T2
(de)
|
1998-10-01 |
2005-12-22 |
Novartis Ag |
Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
|
US20040209849A1
(en)
*
|
1998-11-27 |
2004-10-21 |
Sanochemia Pharmazeutika Aktiengesellschaft |
Use of effectors of the central cholinergic nervous system for treatment of delirium
|
WO2000033840A1
(en)
*
|
1998-12-11 |
2000-06-15 |
Bonnie Davis |
Use of acetylcholinesterase inhibitors on the modulation of the hypothalamic-pituitary-gonadal axis
|
GB9923045D0
(en)
*
|
1999-09-29 |
1999-12-01 |
Novartis Ag |
New oral formulations
|
US6534541B1
(en)
|
1999-10-19 |
2003-03-18 |
Novartis Ag |
Treatment of ocular disorders
|
CA2406383A1
(en)
*
|
2000-04-13 |
2001-10-25 |
Mayo Foundation For Medical Education And Research |
A.beta.42 lowering agents
|
US20040010038A1
(en)
*
|
2002-02-27 |
2004-01-15 |
Eran Blaugrund |
Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
|
WO2004037234A2
(en)
*
|
2002-10-24 |
2004-05-06 |
Merz Pharma Gmbh & Co. Kgaa |
Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
|
CZ293014B6
(cs)
|
2002-10-24 |
2004-01-14 |
Léčiva, A.S. |
Způsob výroby (-)-(S)-3-[1-(dimethylamino)ethyl]fenyl-N-ethyl-N-methylkarbamátu
|
EP1603548A4
(en)
*
|
2003-02-05 |
2007-10-10 |
Myriad Genetics Inc |
COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
|
US7521481B2
(en)
|
2003-02-27 |
2009-04-21 |
Mclaurin Joanne |
Methods of preventing, treating and diagnosing disorders of protein aggregation
|
EP1651195A4
(en)
*
|
2003-07-11 |
2007-10-03 |
Myriad Genetics Inc |
PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
|
AU2004285893B2
(en)
*
|
2003-10-21 |
2011-12-15 |
Colucid Pharmaceuticals, Inc. |
Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
|
GB2409453A
(en)
*
|
2003-12-24 |
2005-06-29 |
Generics |
Process for the preparation of aminoalkyl phenylcarbamates
|
US20070293538A1
(en)
*
|
2004-04-13 |
2007-12-20 |
Myriad Genetics, Incorporated |
Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
|
AU2005241023A1
(en)
*
|
2004-04-29 |
2005-11-17 |
Keystone Retaining Wall Systems, Inc. |
Veneers for walls, retaining walls and the like
|
JPWO2006004201A1
(ja)
*
|
2004-07-01 |
2008-04-24 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
神経再生促進剤
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
CA2618985A1
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
WO2006048720A1
(en)
*
|
2004-11-08 |
2006-05-11 |
Emcure Pharmaceuticals Limited |
An efficient method for preparation of (s)-3-[(1-dimethyl amino)ethyl]-phenyl-n-ethyl-n-methyl-carbamate
|
GB0507298D0
(en)
|
2005-04-11 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
WO2007014124A2
(en)
*
|
2005-07-22 |
2007-02-01 |
Myriad Genetics, Inc. |
High drug load formulations and dosage forms
|
ES2267399B1
(es)
|
2005-08-04 |
2008-02-01 |
Ragactives, S.L. |
Procedimiento para la obtencion de carbamatos de fenilo.
|
JP5116679B2
(ja)
|
2005-09-15 |
2013-01-09 |
株式会社ソニー・コンピュータエンタテインメント |
強度のコンピュータ画像および音声処理、ならびにコンピュータプログラムとインタフェースするための入力装置
|
TWI389709B
(zh)
*
|
2005-12-01 |
2013-03-21 |
Novartis Ag |
經皮治療系統
|
EP1956904B1
(en)
*
|
2005-12-09 |
2017-04-12 |
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
Low-dose ladostigil for the treatment of mild cognitive impairment
|
TW200744576A
(en)
*
|
2006-02-24 |
2007-12-16 |
Teva Pharma |
Propargylated aminoindans, processes for preparation, and uses thereof
|
US7767843B2
(en)
*
|
2006-03-02 |
2010-08-03 |
Apotex Pharmachem Inc. |
Process for the preparation of phenylcarbamates
|
US20080033045A1
(en)
*
|
2006-07-07 |
2008-02-07 |
Myriad Genetics, Incorporated |
Treatment of psychiatric disorders
|
ATE472523T1
(de)
*
|
2006-08-17 |
2010-07-15 |
Alembic Ltd |
Verbessertes verfahren zur herstellung von rivastigmin
|
WO2008037433A1
(en)
|
2006-09-29 |
2008-04-03 |
Synthon B.V. |
Process for making aminoalkylphenyl carbamates and intermediates therefor
|
AU2007309390A1
(en)
|
2006-10-27 |
2008-05-02 |
Medivation Neurology, Inc. |
Methods and combination therapies for treating Alzheimer's disease
|
EP1942100A1
(en)
*
|
2007-01-04 |
2008-07-09 |
Krka Tovarna Zdravil, D.D., Novo Mesto |
Amorphous and crystalline forms of rivastigmine hydrogentartrate
|
CA2677241A1
(en)
*
|
2007-02-02 |
2008-08-14 |
Colucid Pharmaceuticals, Inc. |
Compounds that inhibit cholinesterase
|
US8013181B2
(en)
*
|
2007-04-10 |
2011-09-06 |
Dr. Reddy's Laboratories Limited |
Preparation of rivastigmine and its salts
|
WO2008124969A1
(fr)
*
|
2007-04-16 |
2008-10-23 |
Topharman Shanghai Co., Ltd. |
Méthode de préparation de rivastigmine et de ses intermédiaires
|
US7884121B2
(en)
*
|
2007-06-11 |
2011-02-08 |
Apotex Pharmachem Inc. |
Process for the preparation of phenylcarbamates
|
CA2693110A1
(en)
*
|
2007-07-18 |
2009-01-22 |
Colucid Pharmaceuticals, Inc. |
Methods for promoting wakefulness
|
US8593728B2
(en)
*
|
2009-02-19 |
2013-11-26 |
Toyota Motor Engineering & Manufacturing North America, Inc. |
Multilayer photonic structures
|
US20090082436A1
(en)
*
|
2007-09-26 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched rivastigmine
|
CN101910110B
(zh)
*
|
2008-01-10 |
2013-05-22 |
上海医药工业研究院 |
利凡斯的明的制备方法、其中间体以及中间体的制备方法
|
US8420846B2
(en)
|
2008-08-25 |
2013-04-16 |
Jubilant Life Sciences Limited |
Process for producing (S)-3-[(1-dimethylamino)ethyl] phenyl-N-ethyl-N-methyl-carbamate via novel intermediates
|
US20100087768A1
(en)
*
|
2008-10-02 |
2010-04-08 |
Forlano Paula |
Transdermal drug delivery system for liquid active ingredient
|
GB0823554D0
(en)
*
|
2008-12-24 |
2009-01-28 |
Novartis Ag |
Process for the preparation of optically active compounds using transfer hydrogenation
|
CN101823970B
(zh)
*
|
2009-03-03 |
2013-05-08 |
江苏恩华药业股份有限公司 |
卡巴拉汀及其中间体的合成方法
|
JP6083734B2
(ja)
|
2009-12-22 |
2017-02-22 |
リュイェ ファーマ アーゲーLuye Pharma AG |
リバスチグミンまたはその誘導体を投与するための経皮治療システム
|
US10076502B2
(en)
|
2009-12-22 |
2018-09-18 |
Luye Pharma Ag |
Transdermal therapeutic system for administering rivastigmine or derivatives thereof
|
ES2363395B1
(es)
*
|
2010-01-20 |
2012-02-23 |
Farmalider, S.A. |
Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
|
US20110212928A1
(en)
|
2010-02-09 |
2011-09-01 |
The Johns Hopkins University |
Methods and compositions for improving cognitive function
|
PE20130642A1
(es)
|
2010-03-29 |
2013-06-19 |
Novartis Ag |
Composicion que comprende el peptido amiloide beta 1-6 acoplado a una particula similar a virus y un auxiliar
|
WO2011151359A1
(en)
|
2010-06-02 |
2011-12-08 |
Noscira, S.A. |
Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
|
WO2011151669A1
(en)
|
2010-06-02 |
2011-12-08 |
Jubilant Life Sciences Limited |
Process for producing enantiomerically enriched isomer of 3-(1-aminoethyl) phenyl derivative and employing the same to produce rivastigmine or its pharmaceutically acceptable salt
|
EP2582799B1
(en)
|
2010-06-17 |
2017-12-20 |
Codexis, Inc. |
Biocatalysts and methods for the synthesis of (s)-3-(1-aminoethyl)-phenol
|
MX346185B
(es)
|
2010-11-15 |
2017-03-10 |
Agenebio Inc |
Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo.
|
ES2545094T3
(es)
|
2010-12-14 |
2015-09-08 |
Acino Ag |
Sistema terapéutico transdérmico para la administración de un principio activo
|
CN102786441B
(zh)
|
2011-05-18 |
2013-11-13 |
浙江海正药业股份有限公司 |
利凡斯的明的制备方法、其中间体以及中间体的制备方法
|
WO2012161489A2
(ko)
|
2011-05-20 |
2012-11-29 |
에스케이케미칼 주식회사 |
리바스티그민 함유 패취
|
AR082640A1
(es)
*
|
2011-08-25 |
2012-12-19 |
Amarin Technologies S A |
Un dispositivo para la administracion transdermal de compuestos alcalinos susceptibles a la degradacion en su forma no salificada
|
EP2752188B1
(en)
|
2011-08-31 |
2020-05-06 |
Toyo Ink Sc Holdings Co., Ltd. |
Adhesive patch
|
CN103073456B
(zh)
*
|
2011-10-26 |
2014-03-19 |
连云港润众制药有限公司 |
重酒石酸卡巴拉汀中间体的制备方法
|
EP2594261A1
(en)
|
2011-11-18 |
2013-05-22 |
Labtec GmbH |
Composition for transdermal administration of rivastigmine
|
WO2013142339A1
(en)
|
2012-03-23 |
2013-09-26 |
Novartis Ag |
Transdermal therapeutic system and method
|
ES2449215B1
(es)
*
|
2012-09-17 |
2014-07-14 |
Galenicum Health S.L. |
Solución oral de (S)-3-[1-(dimetilamino)etil]fenil N-etil-N-metilcarbamato
|
KR20140038237A
(ko)
|
2012-09-20 |
2014-03-28 |
에스케이케미칼주식회사 |
리바스티그민의 안정성이 개선된 의약품
|
EP2919788A4
(en)
|
2012-11-14 |
2016-05-25 |
Univ Johns Hopkins |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
|
CN103896787A
(zh)
*
|
2012-12-26 |
2014-07-02 |
江苏康倍得药业有限公司 |
一种卡巴拉汀前体[1-(3-甲氧基苯基)乙基]二甲胺的制备方法
|
WO2014111790A2
(en)
|
2013-01-15 |
2014-07-24 |
Zydus Technologies Limited |
Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
|
US10806717B2
(en)
|
2013-03-15 |
2020-10-20 |
The Johns Hopkins University |
Methods and compositions for improving cognitive function
|
ES2881081T3
(es)
|
2013-03-15 |
2021-11-26 |
Agenebio Inc |
Procedimientos y composiciones para mejorar la función cognitiva
|
CN103319374B
(zh)
*
|
2013-06-09 |
2015-04-22 |
无锡佰翱得生物科学有限公司 |
一种(s)-卡巴拉汀的不对称合成方法
|
WO2015022418A1
(en)
|
2013-08-16 |
2015-02-19 |
Takeda Gmbh |
Treatment of cognitive impairment with pde4 inhibitor
|
US10329301B2
(en)
|
2013-12-20 |
2019-06-25 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
JP6899043B2
(ja)
|
2015-05-22 |
2021-07-07 |
エージンバイオ, インコーポレイテッド |
レベチラセタムの持続放出性医薬組成物
|
US10815242B2
(en)
|
2015-06-19 |
2020-10-27 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
US11505555B2
(en)
|
2016-12-19 |
2022-11-22 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
US20180170941A1
(en)
|
2016-12-19 |
2018-06-21 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
WO2019246300A1
(en)
|
2018-06-19 |
2019-12-26 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
KR20200035359A
(ko)
|
2018-09-26 |
2020-04-03 |
캐딜라 파마슈티클즈 리미티드 |
리바스티그민 제조용 중간체의 합성
|
US20240132513A1
(en)
|
2022-08-19 |
2024-04-25 |
Agenebio, Inc. |
Benzazepine derivatives, compositions, and methods for treating cognitive impairment
|